Mabylon AG

Private

SchlierenHealthcare & Life Scienceshttps://www.mabylon.com/

Last Round

VC Round

Aug 12, 2025

Total Funding Raised

$1.48M

Company Overview

Mabylon AG is a biotechnology company that discovers and develops human-derived antibody therapeutics for the treatment of allergies, inflammation, and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyantibody therapeuticsdrug discoverymonoclonal antibodiesmulti-specific antibodiesb-cell screeningbiotechclinical-stage biotechallergy treatmentneurodegenerative disease researchbiopharmatherapeutic pipelinedrug developmentclinical trialsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mabylon AG Comps

Public and private peers based on sector, stage, and business model.

Mabylon AG comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Mabylon AG Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	Aug 12, 2025
Grant	Sep 24, 2024

View all Funding Rounds

Key People

Founding team and executive leadership

Alcide Barberis

CEO and Director

Executive Team

Tiziana Sonati

Chief Operating Officer

Executive Team

Mabylon AG Investors

Notable investors and investment history

Mabylon AG investors
Investor	Rounds
The ALS Association	Grant
NIH RADx	Grant
Eurostars SME programme	Grant
Target ALS	Grant
Innosuisse	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 4, 2025
Monthly visitors grew 66% MoM, from 427 to 710.

View all signals

Mabylon AG Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Mabylon AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mabylon AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren

Employee Range22

Year Founded2015

Last FundingAug 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.